Last updated: July 17, 2026
Aerie Pharmaceuticals v. Orbicular Pharmaceutical Technologies (3:22-cv-01364) Litigation Summary, Claims, and Exclusivity Risk Analysis
Aerie Pharmaceuticals, Inc. v. Orbicular Pharmaceutical Technologies, LLC (N.D. California, case no. 3:22-cv-01364) is a patent infringement dispute filed in the context of FDA generic/biosimilar-type IP exposure. Public docket records do not provide enough case-specific detail in the available record to produce a complete, accurate summary of the asserted patents, claim construction positions, or litigation posture.
What patents are asserted in Aerie Pharmaceuticals v. Orbicular Pharmaceutical Technologies (3:22-cv-01364)?
Featured answer: Not determinable from the available information.
Which Aerie patent numbers are at issue?
Featured answer: Not determinable from the available information.
Are method-of-use, formulation, or device claims involved?
Featured answer: Not determinable from the available information.
What is the procedural posture in 3:22-cv-01364 (motions, hearings, and scheduling)?
Featured answer: Not determinable from the available information.
Has the court issued claim construction or infringement rulings?
Featured answer: Not determinable from the available information.
What is the current status (e.g., settled, dismissed, trial scheduled)?
Featured answer: Not determinable from the available information.
How do the pleadings map to an ANDA or other FDA pathway for Orbicular?
Featured answer: Not determinable from the available information.
Is this tied to Orange Book-listed patents and Paragraph IV certifications?
Featured answer: Not determinable from the available information.
Are settlement-triggered workarounds or license terms alleged?
Featured answer: Not determinable from the available information.
What does the case seek (injunctive relief, damages, attorneys’ fees)?
Featured answer: Not determinable from the available information.
What remedies are Aerie asking the court to grant?
Featured answer: Not determinable from the available information.
What defenses has Orbicular raised (invalidity, non-infringement, unenforceability)?
Featured answer: Not determinable from the available information.
Which litigation events affect exclusivity timelines or generic launch risk?
Featured answer: Not determinable from the available information.
Does the docket show early dismissal or dispositive motion outcomes?
Featured answer: Not determinable from the available information.
Do any orders or stay provisions impact FDA approval timing?
Featured answer: Not determinable from the available information.
How strong is Aerie’s asserted patent estate in this dispute?
Featured answer: Not determinable from the available information.
What is the likely validity/infringement landscape based on the asserted claims?
Featured answer: Not determinable from the available information.
Are there related litigations involving the same patents or same defendant?
Featured answer: Not determinable from the available information.
What settlement terms typically control business outcomes, and are any reflected in 3:22-cv-01364?
Featured answer: Not determinable from the available information.
Is there evidence of a consent judgment or stipulated dismissal?
Featured answer: Not determinable from the available information.
Are there license scopes, field-of-use limits, or launch date carveouts?
Featured answer: Not determinable from the available information.
What commercial exposure does this litigation create for Orbicular and competing entrants?
Featured answer: Not determinable from the available information.
Could the case block approvals, delay launches, or increase design-around costs?
Featured answer: Not determinable from the available information.
Key Takeaways
- Case-specific details for Aerie Pharmaceuticals, Inc. v. Orbicular Pharmaceutical Technologies (3:22-cv-01364) are not present in the available record to support an accurate litigation summary.
- Without docket and pleading specifics (asserted patents, FDA filing linkage, motion outcomes, and orders), no reliable claim-level, timeline-level, or market-risk analysis can be produced.
FAQs
- What relief is sought in Aerie v. Orbicular Pharmaceutical Technologies (3:22-cv-01364)?
- Did the court issue a claim construction order in 3:22-cv-01364?
- Which asserted patents does Aerie claim are infringed by Orbicular?
- Is 3:22-cv-01364 tied to a specific FDA product and Paragraph IV certification?
- What is the settlement or dismissal status of 3:22-cv-01364?
References
(No citable sources were provided in the available record.)
